The year’s other big depression data
About a week after Sage Therapeutics’ disappointing results in a major depression study, Axsome Therapeutics is on deck to disclose data of its own, and the market seems optimistic.
Axsome’s share price has nearly doubled since Nov. 1, driven largely by hopes that AXS-05, a combination treatment, can succeed in a pair of studies expected to read out before the year ends. It’s a high-stakes proposition. According to SVBLeerink, a complete failure would take Axsome’s stock back down to single digits, while two success would double its value.
That all comes with the caveat that clinical trials in depression are notoriously difficult — and difficult to predict — which is to say nothing of the skepticism tied to AXS-05, which combines an ingredient found in cough suppressants with generic Wellbutrin.
Axsome’s share price has nearly doubled since Nov. 1, driven largely by hopes that AXS-05, a combination treatment, can succeed in a pair of studies expected to read out before the year ends. It’s a high-stakes proposition. According to SVBLeerink, a complete failure would take Axsome’s stock back down to single digits, while two success would double its value.
That all comes with the caveat that clinical trials in depression are notoriously difficult — and difficult to predict — which is to say nothing of the skepticism tied to AXS-05, which combines an ingredient found in cough suppressants with generic Wellbutrin.
No hay comentarios:
Publicar un comentario